Verdict No. 3046 · Search date 2026-09-08 · Methodology v1.0
Phytosomal curcumin 250 mg/day as adjunctive therapy,
does it really help with Reduction of migraine-attack frequency in adults with migraine without aura?
30-Second Summary
C
Evidence Grade C · 46 · Safety caution
CGRP and inflammatory-marker papers and omega-3/CoQ10 combinations were excluded as independent clinical-frequency replications.
Caution. No adverse effects were reported, but 65 completers over eight weeks cannot exclude rare harms or long-term add-on risks.
What the
research showsGrade C with 46 points. A 70-randomized, 65-completer trial abstract reports improved attack frequency after phytosomal curcumin 250 mg/day for eight weeks, but the exact frequency-specific between-group change, 95% CI, P value, and single prespecified hierarchy were not verified. P=.052 belongs to a separate 2021 conventional-curcumin 500-mg twice-daily trial and is not transferred to this formulation.
research showsGrade C with 46 points. A 70-randomized, 65-completer trial abstract reports improved attack frequency after phytosomal curcumin 250 mg/day for eight weeks, but the exact frequency-specific between-group change, 95% CI, P value, and single prespecified hierarchy were not verified. P=.052 belongs to a separate 2021 conventional-curcumin 500-mg twice-daily trial and is not transferred to this formulation.
What the
ads claimGeneric turmeric, nano formulations, and combinations cannot inherit this result, and preventive medication replacement was not tested.
ads claimGeneric turmeric, nano formulations, and combinations cannot inherit this result, and preventive medication replacement was not tested.
Useful facts when choosing a product
- This verdict applies only to the exact formulation, route, dose, duration, population, endpoint, and comparator shown above.
- Conventional curcumin, turmeric powder, nano or micellar products, phospholipid phytosomes, piperine combinations, swallowed products, and topical oral products are not interchangeable.
- Caution. No adverse effects were reported, but 65 completers over eight weeks cannot exclude rare harms or long-term add-on risks.
Chamgap Semantic Classification Code
Permanent code issued
S.phytosomal-curcumin.oral.migraine-attack-frequency.reduce.addonSupplements and nutraceuticals > Phytosomal curcumin > Oral > Migraine-attack frequency > Reduction claim > Add-on to standard treatment
Bound to the 250-mg/day eight-week phytosomal formulation; nano, omega-3, and CoQ10 combinations remain separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Phytosomal curcumin |
| Source or part used | Curcumin derived from Curcuma longa in a phospholipid delivery system |
| Formulation or processing | Phytosomal curcumin, distinct from nanocurcumin |
| Route | Oral |
| Dose | 250 mg/day |
| Duration | Eight weeks of treatment and follow-up |
| Population | Adults with migraine without aura continuing standard treatment |
| Effect or condition | Reduction of migraine-attack frequency |
| Primary endpoint | Change in attack frequency at eight weeks; single prespecified primary unverified |
| Comparator | Maltodextrin placebo added to standard treatment |
| Duplicate-detection key | phytosomal-curcumin|phospholipid-oral|oral|adult-migraine-without-aura|attack-frequency-reduction|8-weeks |
Gap Measurement · Verdict 3046 · C 46
What the research actually shows
A trial randomized 70 adults with migraine without aura to phytosomal curcumin or maltodextrin for eight weeks.
Why this is classified as C (46)
The formulation-specific double-blind signal is retained, but unverified exact between-group frequency effect, 95% CI, single prespecified primary, and ITT denominator impose EX/CX limits, yielding C with 46 points.
Counterpoint. The registered double-blind placebo trial is directionally favourable in the abstract, but incomplete denominators, multiple clinical outcomes, and missing exact estimates cannot be converted into a confirmed effect.
Rejudgment record. Independent Codex cross-check — One formulation, one route, one population, one claim, one principal endpoint and comparator
Scoring profile behind this grade
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Effect and Safety of Phytosomal Curcumin Supplementation on Migraine Patients: A Randomized, Double-Blind and Placebo-Controlled Trial | The cited design and its allocation, masking, endpoint, and analysis limitations were independently checked. | 32 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint is preserved; secondary and mechanistic outcomes remain separate. | The verified numerical result is preserved in the English reader answer and rationale; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and verified analysis limitations. |
| Effects of Curcumin Supplementation on Clinical Features and Inflammation, in Migraine Patients: A Double-Blind Controlled, Placebo Randomized Clinical Trial | The cited design and its allocation, masking, endpoint, and analysis limitations were independently checked. | 44 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint is preserved; secondary and mechanistic outcomes remain separate. | The verified numerical result is preserved in the English reader answer and rationale; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and verified analysis limitations. |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-09-08).
Shojaei M et al. Chin J Integr Med. 2025;31:963-972. PMID: 41136816. DOI: 10.1007/s11655-025-3939-1. IRCT20201129049534N2.
checkedRezaie S et al. Int J Prev Med. 2021;12:161. PMID: 35070194. PMCID: PMC8724631. DOI: 10.4103/ijpvm.IJPVM_405_20.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Phytosomal Curcumin for Migraine Attack Count—A Positive Abstract Without a Verified Exact Contrast — Evidence Grade C·46. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/oral-phytosomal-curcumin-adjunct-episodic-migraine-frequency/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.